Cells4Life

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2021 Financial Results

Retrieved on: 
Wednesday, November 18, 2020

HONG KONG, Nov. 18, 2020 /PRNewswire/ --Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the secondquarter and first half of fiscal year 2021 on Tuesday, November 24, 2020, after the U.S. market close.

Key Points: 
  • HONG KONG, Nov. 18, 2020 /PRNewswire/ --Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the secondquarter and first half of fiscal year 2021 on Tuesday, November 24, 2020, after the U.S. market close.
  • ET on Wednesday, November 25, 2020 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Stem Cell Umbilical Cord Blood Market to Reach $10.13 Bn, Globally, by 2027 at 16.9% CAGR: Allied Market Research

Retrieved on: 
Wednesday, August 26, 2020

"According to the report, the global stem cell umbilical cord blood industry was estimated at $3.11 billion in 2019, and is anticipated to hit $10.13 billion by 2027, registering a CAGR of 16.9% from 2020 to 2027.

Key Points: 
  • "According to the report, the global stem cell umbilical cord blood industry was estimated at $3.11 billion in 2019, and is anticipated to hit $10.13 billion by 2027, registering a CAGR of 16.9% from 2020 to 2027.
  • Also, the first phase of the lockdown put off many healthcare companies from investing in the research and commercialization of cord blood stem cell therapies.
  • Based on application, the regenerative medicine segment accounted for nearly three-fifths of the global stem cell umbilical cord blood market share in 2019 and is projected to lead the trail till 2027.
  • Based on geography, North America generated the major share in 2019, garnering more than two-fifths of the global stem cell umbilical cord blood market.

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021

Retrieved on: 
Monday, August 24, 2020

Revenues increased by 2.8% YoY to RMB280.9 million ($39.8 million) in the first quarter of fiscal 2021.

Key Points: 
  • Revenues increased by 2.8% YoY to RMB280.9 million ($39.8 million) in the first quarter of fiscal 2021.
  • Depreciation and amortization expenses for the first quarter were RMB12.4 million ($1.7 million), similar to that in the prior year period.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020

Retrieved on: 
Wednesday, March 11, 2020

Revenues increased by 31.7% YoY to RMB334.7 million ($48.1 million) in the third quarter of fiscal 2020.

Key Points: 
  • Revenues increased by 31.7% YoY to RMB334.7 million ($48.1 million) in the third quarter of fiscal 2020.
  • For the first nine months of fiscal year 2020, total revenues increased by 25.4% YoY to RMB921.6 million ($132.4 million).
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020

Retrieved on: 
Tuesday, November 26, 2019

Revenues increased by 26.9% YoY to RMB313.5 million ($43.9 million) in the second quarter of fiscal 2020.

Key Points: 
  • Revenues increased by 26.9% YoY to RMB313.5 million ($43.9 million) in the second quarter of fiscal 2020.
  • For the first half of fiscal year 2020, total revenues increased by 22.0% YoY to RMB586.8 million ($82.1 million).
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020

Retrieved on: 
Tuesday, August 27, 2019

Revenues increased by 16.9% to RMB273.4 million ($39.8 million) in the first quarter of fiscal 2020.

Key Points: 
  • Revenues increased by 16.9% to RMB273.4 million ($39.8 million) in the first quarter of fiscal 2020.
  • The Company reclassified 389 private cord blood units as donated cord blood units during the three months ended June 30, 2019 after the Company determined that the recoverability of these prior private cord blood banking subscribers was remote.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal

Retrieved on: 
Thursday, June 6, 2019

The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu and Ms. Jennifer J. Weng, each of whom currently serves as an independent director on the Board, with Mr. Chen serving as the chair of the Special Committee.

Key Points: 
  • The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu and Ms. Jennifer J. Weng, each of whom currently serves as an independent director on the Board, with Mr. Chen serving as the chair of the Special Committee.
  • The Special Committee intends to retain advisors, including an independent financial advisor and U.S. and Cayman Islands legal counsels, to assist it in its evaluation.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2019 Financial Results

Retrieved on: 
Tuesday, February 19, 2019

HONG KONG, Feb. 19, 2019 /PRNewswire/ --Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release its unaudited financial results for the thirdquarter and first nine months of fiscal year 2019 on Monday, February 25, 2019, after the market close.

Key Points: 
  • HONG KONG, Feb. 19, 2019 /PRNewswire/ --Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release its unaudited financial results for the thirdquarter and first nine months of fiscal year 2019 on Monday, February 25, 2019, after the market close.
  • ET on Tuesday, February 26, 2019 to discuss its financial performance and provide an overview of the Company's recent developments, followed by a question and answer session.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood bankingoperator with multiplelicenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.